HCA Healthcare stock has delivered a solid multi year gain, yet recent share price softness and a strong value score suggest the market may not fully reflect what investors are paying for at the current US$414.45 level.
- Over 5 years, HCA Healthcare shares have returned 70.9%, which puts the recent weaker patch into context for longer term holders.
- Future returns can depend heavily on how well HCA Healthcare manages hospital capacity and cost control, while pressure on reimbursement rates and staffing expenses may limit how much value the company can pass through to shareholders.
- On a broad set of valuation checks, HCA Healthcare screens as relatively cheap, with a high value score of 5, which points to an undervalued multiple story.
The issue now is whether the current price already captures HCA Healthcare's risks and opportunities, or if the strong value checks suggest more room for upside over time.
Scan how HCA Healthcare compares on valuation and quality by lining it up against hand picked peers in 45 high quality undervalued stocks.Is HCA Healthcare Still Cheap on Earnings?
The P/E ratio is a useful way to see what you are paying today for each dollar of HCA Healthcare's earnings. On this measure, HCA Healthcare trades on about 13.1x earnings, which is lower than both its healthcare industry average of roughly 24.8x and a peer group average of about 15.5x.
A P/E multiple for HCA Healthcare, based on the model that blends its scale, margins, sector profile and risk, is around 26.9x. That is roughly double the current 13.1x level, which indicates a sizeable gap between what the model suggests investors might be willing to pay and what the market is actually paying today.
On the P/E measure, HCA Healthcare stock appears undervalued compared with both peers and the modelled multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The HCA Healthcare Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for HCA Healthcare pick up where the valuation puzzle leaves off and set out the specific assumptions on future growth, margins and earnings that would need to hold for HCA Healthcare's stock to be worth materially more or less than today. Rather than giving a single figure, they spell out the future that figure relies on so you can watch how the real business performance lines up over time. They are available on Simply Wall St's Community page.
Community views on HCA Healthcare are pulled in opposite directions, with some investors focused on scale and consistency while others worry about payer mix and margins.
Bull case: 34% undervalued
"HCA isn’t a speculative healthcare bet. It’s a foundational one. As populations age and care delivery continues shifting toward efficiency and integration, companies with scale, systems, and experience tend to win quietly..."
Read the full Bull Case to see why HCA Healthcare could be undervalued
Bear case: 9% overvalued
"There is higher acuity in areas like cardiac care, trauma and rehab. However, payer mix shifts tied to exchanges, growth in uninsured equivalent admissions and slower Medicaid conversions could keep uncompensated care and patient balance collections elevated, placing a ceiling on revenue yield and adjusted EBITDA margins..."
Read the full Bear Case to see why HCA Healthcare could be overvalued
Do you think there's more to the story for HCA Healthcare? Head over to our Community to see what others are saying!
The Bottom Line
HCA Healthcare screens as undervalued on market multiples, with the current P/E well below both sector and peer averages and also below the tailored multiple implied by its profile. The broader valuation checks support the idea that investors are paying a discounted price for the earnings on offer rather than an already full one. From here, the key question is whether HCA Healthcare can keep capacity, reimbursement and staffing pressures in enough balance to avoid that discount turning into a value trap instead of an opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com